Harish Mahalingam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Harish Mahalingam has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Anthony V. Rawlings
AVR Consulting, Ltd., Cheshire, UK
1 shared publication- Christoph F. Gfeller
GlaxoSmithKline Consumer Healthcare, Medical Affairs Skin Health, Weybridge, Surrey, UK
1 shared publication Connie B. Lin
GlaxoSmithKline Consumer Healthcare, R&D Innovation Skin Health, Collegeville, PA, USA
1 shared publication- David J. Moore
GSK Consumer Healthcare, Skin Health R&D, Weybridge, UK
1 shared publication Gary Grove
CyberDERM, Inc., Broomall, PA, USA
1 shared publicationGilbert Shanga
GSK Consumer Healthcare, Biostatistics, Warren, NJ, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 193-208
A series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis
Purpose: These studies describe the testing of a novel, daily-use lip cream designed for individuals with lips prone to recurrent herpes labialis (RHL) that protects against environmental triggers. Subjects and methods: In vitro occlusive and in vitro and in vivo photoprotection analyses, a characterization of normal vs dry lips, and a randomized, evaluator-blinded, clinical trial that assessed the lip cream in healthy subjects with dry lips were conducted. In the clinical trial, subjects applied the lip cream or were untreated and evaluated using transepidermal water loss (TEWL), corneometry, visual assessments of lip dryness, expert photographic evaluations, and subject-rated outcomes. Results: The lip cream’s in vitro water vapor transmission rate (84.1 g/(m2 h)) indicated moderate occlusivity. The lip cream, but not placebo or control (water), reduced ultraviolet A (UVA)- and UVB-induced DNA damage, and tumor necrosis factor-α (EpiDermFT) and prostaglandin E2 release (EpiDermFT and EpiGingival™). The lip cream’s in vivo sun protection factor (SPF) was 12.2 (lower confidence limit, 11.3) and SPF/UVA protection factor ratio was 0.9. The characterization of dry vs normal lips identified differences in moisturization. In the clinical trial, the lip cream significantly decreased TEWL (difference: –7.19 [95% CI: −11.41, –2.98]; PPPP< 0.05), cupping (difference: –1.50 [95% CI: −2.30, –0.70]; PPP=0.51). Subject-rated assessments indicated improvements in cracking, dryness, and flaking in the lip cream group but worsening in untreated subjects. Conclusion: These studies indicate that this novel, daily-use lip cream protects against UV radiation, drying, and chapping, which are established environmental RHL triggers.
- 1 March 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 193-208
Open AccessA series of in vitro and human studies of a novel lip cream formulation for protecting against environmental triggers of recurrent herpes labialis
Purpose: These studies describe the testing of a novel, daily-use lip cream designed for individuals with lips prone to recurrent herpes labialis (RHL) that protects against environmental triggers. Subjects and methods: In vitro occlusive and in vitro and in vivo photoprotection analyses, a characterization of normal vs dry lips, and a randomized, evaluator-blinded, clinical trial that assessed the lip cream in healthy subjects with dry lips were conducted. In the clinical trial, subjects applied the lip cream or were untreated and evaluated using transepidermal water loss (TEWL), corneometry, visual assessments of lip dryness, expert photographic evaluations, and subject-rated outcomes. Results: The lip cream’s in vitro water vapor transmission rate (84.1 g/(m2 h)) indicated moderate occlusivity. The lip cream, but not placebo or control (water), reduced ultraviolet A (UVA)- and UVB-induced DNA damage, and tumor necrosis factor-α (EpiDermFT) and prostaglandin E2 release (EpiDermFT and EpiGingival™). The lip cream’s in vivo sun protection factor (SPF) was 12.2 (lower confidence limit, 11.3) and SPF/UVA protection factor ratio was 0.9. The characterization of dry vs normal lips identified differences in moisturization. In the clinical trial, the lip cream significantly decreased TEWL (difference: –7.19 [95% CI: −11.41, –2.98]; PPPP< 0.05), cupping (difference: –1.50 [95% CI: −2.30, –0.70]; PPP=0.51). Subject-rated assessments indicated improvements in cracking, dryness, and flaking in the lip cream group but worsening in untreated subjects. Conclusion: These studies indicate that this novel, daily-use lip cream protects against UV radiation, drying, and chapping, which are established environmental RHL triggers.